EUVIMEDDécouvrir EUVIMED
Systematische ÜbersichtNetzwerk-MetaanalyseOpen access · CC BY 4.0

Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan

Sameed Qureshi, Kamran Amir Khan, Aamir Wisal, Ramsha Khan, Hamza Ahmad

Pakistan Journal of Gastroenterology · 2026

DOI: 10.63521/641kea29 ↗

At a glance

Systematische Übersicht in Pakistan Journal of Gastroenterology, 2026. Written by Sameed Qureshi and 4 co-authors. The full text is freely available (open access, CC BY 4.0).

RésuméRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a rapidly growing public health challenge in Pakistan and South Asia due to rising prevalence of obesity, type 2 diabetes, and metabolic syndrome. Pharmacological options beyond lifestyle modification are essential for patients with moderate-to-advanced fibrosis (F2–F3). This systematic review synthesizes comparative efficacy data on resmetirom (thyroid hormone receptor-β agonist), GLP-1 receptor agonists (e.g., semaglutide), and pioglitazone for key histological endpoints: MASH resolution without worsening of fibrosis and fibrosis improvement (≥1 stage) without worsening of MASH.

Methods

Following PRISMA guidelines, a systematic search was conducted in PubMed, Embase, PMC, PakMediNet, and Google Scholar from January 2015 to July 2025. Eligible studies included phase 3 randomized controlled trials (RCTs) and network meta-analyses reporting histological outcomes in biopsy-proven MASH. Data on responder rates, relative risks (RR), odds ratios (OR), and surface under the cumulative ranking curve (SUCRA) rankings were extracted from high-quality sources. Random-effects model summaries and heterogeneity assessments (I²) were noted from published network meta-analyses. Pakistan-specific epidemiological and access data were integrated for contextual relevance.

Results

Network meta-analyses (29 RCTs, n>9,000) ranked pegozafermin highest for both endpoints, followed by tirzepatide, resmetirom, and semaglutide. In MAESTRO-NASH (n=966, F2–F3), resmetirom 100 mg achieved MASH resolution in 29.9% vs. 9.7% placebo and fibrosis improvement in 25.9% vs. 14.2% placebo. In ESSENCE (interim, n=800 at week 72), semaglutide 2.4 mg achieved MASH resolution in 62.9% vs. 34.3% placebo and fibrosis improvement in 36.8% vs. 22.4% placebo. Pioglitazone showed modest effects (RR 2.29 for resolution). In Pakistan, MASLD prevalence ranges 14–38.9%, with limited access to newer agents.

Conclusions

Resmetirom and GLP-1 RAs demonstrate superior histological efficacy compared to pioglitazone. In resource-limited settings like Pakistan, a tiered approach prioritizing affordable therapies, non-invasive monitoring, and local research is recommended to address the growing burden.

Cite

APA

Qureshi, S., Khan, K. A., Wisal, A., Khan, R., & Ahmad, H. (2026). Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan. Pakistan Journal of Gastroenterology. https://doi.org/10.63521/641kea29

Vancouver

Qureshi S, Khan KA, Wisal A, Khan R, Ahmad H. Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan. Pakistan Journal of Gastroenterology. 2026. doi:10.63521/641kea29

BibTeX
@article{Qureshi2026,
  author = {Qureshi, Sameed and Khan, Kamran Amir and Wisal, Aamir and Khan, Ramsha and Ahmad, Hamza},
  title = {Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan},
  journal = {Pakistan Journal of Gastroenterology},
  year = {2026},
  doi = {10.63521/641kea29}
}
Start for free →